Análisis de la acción EyePoint Inc (EYPT)EYPTEyePoint Inc

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

EyePoint Pharmaceuticals is not a good buy right now due to its current price of $0.4045, which reflects an 80% drop following the failure of its Phase 3 LUCIA trial. The RSI is extremely low at 7.065, indicating oversold conditions, but the company's fundamentals are deteriorating with a forward P/E of 6.1614 and a net income loss of -94,470,000 USD in Q2 2026. The main risk is the significant uncertainty surrounding its regulatory path and future trials, which could further impact its stock price negatively.